Apr 13, 2021 8:30am EDT Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update
Apr 12, 2021 8:30am EDT Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Mar 19, 2021 10:00am EDT Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development
Mar 11, 2021 7:10am EST Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd
Mar 09, 2021 8:30am EST Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors
Mar 02, 2021 8:30am EST Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
Feb 17, 2021 8:30am EST Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal
Feb 16, 2021 8:30am EST Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer
Feb 08, 2021 8:30am EST Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants
Feb 02, 2021 8:30am EST Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia
